News Alert: Nitto Denko Avecia Inc. (Avecia) announced today the opening of its new oligonucleotide API (active pharmaceutical ingredients) manufacturing facility in Milford, MA. The opening will commence with a ribbon cutting ceremony in August 2017 onsite at the Milford, MA facility. Read our press release to learn more.
News Alert: Nitto Avecia Announces Multiple Oligonucleotide Expansions - We are excited to share more exciting news on our continued plans to expand the company’s analytical development and oligonucleotide manufacturing capacities. Read our press release to learn more about the expansions at our Milford and Marlboro, MA and Irvine, CA sites.
Exciting News! Nitto Denko Avecia Inc. (Avecia) entered into a definitive agreement to acquire the assets of Irvine Pharmaceutical Services (Irvine) and Avrio Biopharmaceuticals (Avrio), both located in Irvine, CA. We will consolidate these two businesses into a newly established company – Nitto Avecia Pharma Services Inc. Read more.
With over 20 years of experience in oligonucleotide development and production, and over 1000 sequences manufactured, Avecia has played an integral role in the advancing oligo therapeutic market. Our mission is to continue to build value for our customers, as they progress through drug development into commercialization. And as a member of the Nitto Denko Corporation (www.nitto.com), Avecia is committed to the future of the oligonucleotide market. We are driven by innovative ideas and flexible solutions, designed to provide our customers with the best in service, quality, and technology.
Our FDA inspected facilities
in Milford, MA and Cincinnati, OH are aligned to the needs of the pre-clinical, clinical, and launched product oligonucleotide markets. Our aim is to leverage our wealth of experience, and our understanding of the regulatory needs in each of these segments, to ensure we exceed our customer’s expectations.